Delayed Acquisition of Rectovaginal GBS Colonization: A Hidden Benefit of GBS Conjugate Vaccines

10/10/2018

Presented by Lawrence C. Paoletti, PhD

Editor's Note: At 12:03 when red and blue boxes are mentioned, the correct reference is to the red and yellow boxes showing GBS types

Measurable Learning Objectives:
At the conclusion of this presentation, participants should be able to…
1. Relate a history of GBS conjugate vaccine development.
2. Discuss results from a clinical study to determine if an immunogenic GBS vaccine can reduce the time to first vaginal colonization by GBS.

ABOUT THE PRESENTER:

Lawrence C. Paoletti, PhD
Dr. Lawrence Paoletti is a microbiologist with over 25 years of experience in the development and testing of group B streptococcal vaccines for use in humans. He is an author on over 70 scientific papers, review articles and book chapters relating to GBS disease prevention.

Larry Paoletti

10/19/2018 07:36:08 am

I'll be happy to try to answer any questions on GBS vaccine development. I'm also happy to share the link (https://doi.org/10.1093/cid/ciy838) to our recently accepted paper on the SPIN trial mentioned in my presentation.

Marti Perhach

10/19/2018 08:43:05 am

Thank you, Dr. Paoletti, for your outstanding presentation and congratulations on your recently accepted paper!

Does it appear that race or age of the women studied can influence the delayed acquisition of vaginal and rectal GBS III colonization?

Larry Paoletti

10/20/2018 01:30:45 pm

Good question. What we state in the paper is: “Non-white women and those 30 through 40 years of age had higher CPS III-specific serum antibody levels 1-month post-immunization compared to white women (log rank test, 5.97; P = 0.01) (Supplementary Figure 1) and those 18-21 years of age (log rank test; 14.48; P < 0.0001) (Supplementary Figure 2), respectively.” Since transudate serum IgG is thought to prevent colonization then, yes both age and race could impact colonization rates due to the antibody responses.

Comments are closed.